I'm a married to a beautiful Holy Ghost filled lady. I'm a Oneness Apostolic that still believes Holiness and unity matter. 9yrs myeloma survivor. God is good.
#Myeloma Paper of the Day: Phase 1 first-in-human trial of natural ligand-based CAR T targeting BCMA & TACI (TriPRIL) in RRMM shows 80% ORR & 53% CR (56% among those w/ prior BCMA CAR) w/ 87% CRS rate (all grade 1) & 1 event each of ICANS & IEC-HS: https://t.co/rfxzABNKx0. #mmsm
🚨Newly released 911 audio and surveillance footage expose the terrifying final moments of 68 year old Frank Imhoff, who was killed while simply loading his trailer at a Port Neches, Texas, storage facility.
According to investigators, the Nederland resident was working outside his pickup truck when a suspect identified as Dekovin Flanagan Jr. suddenly leaped across the hood of the vehicle and stole it. As the truck sped off, Imhoff was run over, suffering fatal injuries.
Flanagan was later tracked down and apprehended by law enforcement at a nearby apartment complex. He is currently being held on a $1 million bond facing murder charges.
Investigators are still piecing together a motive, noting that it remains entirely unclear why Imhoff's truck was targeted or what triggered the violent escalation.
Case Backstory & Investigation Details
The fatal incident occurred on August 16, 2026, at Central Maxi Storage located on Ridgewood Drive in Port Neches, Texas.
The Victim: 68 year old Frank Cameron Imhoff of Nederland, Texas, was a dedicated father and grandfather affectionately known as "Campa" to his grandchildren.
Family members noted that he was hardworking and would naturally try to protect his livelihood.
According to the Port Neches Police Department and investigative affidavits, the suspect identified as Dekovin Keith Flanagan Jr. (21, of Port Arthur, Texas) had initially wandered into and rummaged through an unoccupied storage unit on the property.
Flanagan then sprinted out, hopped the hood of Imhoff’s pickup truck while it was being loaded with a trailer, forced his way into the driver's seat, and attempted to speed away.
As Flanagan accelerated in the stolen vehicle, surveillance footage captured Imhoff running alongside the driver's side trying to stop the theft before being knocked down and run over by his own truck and trailer.
Following a chaotic morning that involved erratic behavior and property destruction at a nearby apartment complex, law enforcement tracked Flanagan down to the Ridgewood Apartments, where officers found him hiding in a closet.
Dekovin Keith Flanagan Jr.’s specific upcoming trial date or docket appearance has not yet been publicly scheduled or published in local court records.
#FrankImhoff
#PortNeches
#PortNechesTX
#SoutheastTexas
#TexasNews
#InvestigativeJournalism
#JusticeForFrankImhoff
#Myeloma Paper of the Day: An open agentic AI co-scientist for clinical and biomedical discovery generated multiple myeloma hypotheses validated in an external cohort with attenuated signal in randomized controls: https://t.co/NOsPyGH5gj. #mmsm
🧬 CAR-T and bispecific antibodies in relapsed multiple myeloma
🎙️ Presented by Dr. Ghazi Alotaibi at BMT & CGT 2026.
📊 What the randomized phase 3 trials showed
PFS and OS hazard ratios below are versus each trial’s own control.
🔵 CARTITUDE-4 | Carvykti (cilta-cel)
After 1–3 prior lines in lenalidomide-refractory disease, 30-month PFS was 59% vs 26%. PFS HR 0.29 and OS HR 0.55.
🔵 KarMMa-3 | Abecma (ide-cel)
After 2–4 prior lines in triple-class–exposed disease, median PFS was 13.8 vs 4.4 months (HR 0.49). The unadjusted OS HR was 1.01, with 56% of control patients crossing over.
🟣 MajesTEC-3 | Tecvayli (teclistamab) + daratumumab
After 1–3 prior lines, 36-month PFS was 83% vs 30%. PFS HR 0.17 and OS HR 0.46. Only about 5% had prior anti-CD38 exposure. The FDA approved the combination after ≥1 prior line that included a proteasome inhibitor and an IMiD.
🟣 MajesTEC-9 | Teclistamab monotherapy
After 1–3 prior lines that included lenalidomide and an anti-CD38 antibody, 18-month PFS was 70% vs 27%. PFS HR 0.29 and OS HR 0.60. Prior anti-CD38 exposure is an important distinction when applying these results.
🟠 MonumenTAL-3 | Talvey (talquetamab) + daratumumab ± pomalidomide
PFS HRs were 0.33 without pomalidomide and 0.28 with it, each versus daratumumab–pomalidomide–dexamethasone. Corresponding OS HRs were 0.51 and 0.47.
🎯 Later-line options and logistics
BCMA CAR-T is a single infusion after apheresis, manufacturing, and lymphodepletion. Investigational anito-cel achieved a 96% response rate and estimated 62% PFS at 24 months in the single-arm iMMagine-1 study.
BCMA bispecifics include Tecvayli (teclistamab), Elrexfio (elranatamab), and Lynozyfic (linvoseltamab). Talvey (talquetamab) targets GPRC5D. Bispecifics use step-up dosing followed by repeated treatment, with intervals that vary by product and response.
⚠️ Toxicity pearls
🌡️ CRS and ICANS can occur with either platform. Grade CRS, assess for infection, and use serial ICE scores when neurotoxicity is suspected.
🧠 Delayed neurotoxicity after cilta-cel can present with new tremor, gait change, or facial weakness. Persistent diarrhea warrants evaluation for immune effector cell–associated enterocolitis as well as infection.
🦠 Infections and cytopenias require follow-up beyond the acute toxicity window. Trend counts and IgG, plan antimicrobial prophylaxis, and consider IVIG when indicated.
🔬 IEC-HS should enter the differential when ferritin rises with worsening cytopenias, falling fibrinogen, or transaminitis as CRS resolves.
🍽️ Talquetamab can affect taste, oral intake, skin, and nails. Ask about eating and track weight early.
📌 Prior anti-CD38 exposure, disease tempo, time to CAR-T infusion, and the patient’s ability to sustain repeated treatment all matter when choosing a strategy. The trials used different populations and control regimens, so their hazard ratios cannot rank CAR-T against bispecifics.
#MultipleMyeloma #CART #BispecificAntibodies #BCMA #GPRC5D #KFSHRC
#Myeloma Paper of the Day: Home grown autologous fully-human 3rd-generation CD20-directed CAR-T containing CD28 & 41BB costimulatory domains shows CR/VGPR rate of 80% in heavily pre-treated patients w/ low CRS rate & 2-year PFS of 68.6% & OS of 90%: https://t.co/ay6FbMfPsn. #wmsm
@kingdomspeak 3) Scripture teaches me to not be a judge.
If you ask, I will share what I believe, if you don't ask and God puts it on my heart, I will pray for you. But I won't judge you. God Bless. I enjoyed your perspective.
@kingdomspeak 2) Like you mentioned here, I've always taught my boys, don't look down on another church because there's another church looking down his nose at you.
I really believe in holiness and strive for it.
#Myeloma Paper of the Day: Simplified Frailty Index & Memorial Sloan Kettering Frailty Index classify partially overlapping but distinct RRMM pts getting CAR T; binary SFI not assoc w/ efficacy/safety, continuous MSK-FI independently assoc w/ PFS: https://t.co/QUHGAgcfaR. #mmsm
#Myeloma Paper of the Day: Study on impact of initial & subsequent zanubrutinib dosing in #Waldenström pts finds sub-standard initiation predicted lower VGPR & worse PFS while subsequent toxicity-driven reductions after standard initiation did not: https://t.co/1VDrqEvidM. #wmsm
#Myeloma Paper of the Day: Single institutional experience of #Waldenstrom macroglobulinemia in siblings finds median OS of 230 months for pts w/ familial WM among siblings and 96 months for those with sporadic WM (p = 0.2, HR: 0.6, 95% CIs: 0.2-1): https://t.co/45FCwmNFz7. #wmsm
@PlumblineFaith So what you saying g is " pastor " as we know it didn't really come about until the 4th century..similarly to how trinity didn't come about until centuries after the church started in the book of Acts, and really take root until 325AD.
#Myeloma Paper of the Day: Abnormal bone marrow volume based on whole-body dixon MRI may be associated with with prognosis (PFS HR = 1.88, 95% CI = 1.10-3.24, p = 0.022; OS HR = 2.71, 95% CI = 1.31-5.58, p = 0.007) in newly diagnosed myeloma: https://t.co/nq9Wt0nRhc. #mmsm
#Myeloma Paper of the Day: Dutch study of 35-yr trends in incidence/survival for myeloma finds significant survival improvements in each age group but age-related differences persist related to comorbidities & diminished treatment tolerability: https://t.co/ZZXarbGFaN. #mmsm
#Myeloma Paper of the Day: US Myeloma Immunotherapy Consortium data on impact of extramedullary plasmacytoma on outcomes in RRMM pts (N=360) txd w/ talquetamab find preserved response rates (63-68%) in EMD & PSD but shorter PFS (4.3-7.8 mos) & OS: https://t.co/OphpXqSivo. #mmsm